Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab Plus Fruquintinib as Adjuvant Treatment for High-Risk Non-Clear Cell Renal Cell Carcinoma
NCT07904156Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2026
- Primary completion
- Dec 2030
01
Overview
Phase 3, randomised, open-label trial in non-clear cell renal cell carcinoma (nccRCC) comparing Serplulimab Plus Fruquintinib with Observation (2 arms). Primary endpoint: Recurrence-Free Survival Rate at 2 years. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
serplulimabfruquintinib
03
Conditions
non-clear cell renal cell carcinoma (nccRCC)
Beyond the preview
Go deeper on NCT07904156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07904156.